What to do with a clinical trial with conflicts of interest

BMJ Evidence-Based Medicine

Volumn 25, Issue 5, 2020, Pages 157-158

  Lundh, Andreas ^a,b,c   Boutron, Isabelle ^d,e,f   Stewart, Lesley ^g   Hróbjartsson, Asbjorn ^a,b  

^a ODENSE UNIVERSITY HOSPITAL   (Denmark)

^b UNIVERSITY OF SOUTHERN DENMARK   (Denmark)

^c HVIDOVRE HOSPITAL   (Denmark)

^d PARIS DESCARTES UNIVERSITY   (France)

^e UNIVERSITÉ PARIS DESCARTES   (France)

^f Cochrane France ^*  (France)

^g UNIVERSITY OF YORK   (United Kingdom)

Author keywords

medical ethics

Indexed keywords

CLINICAL TRIAL (TOPIC); CONFLICT OF INTEREST; DRUG SCREENING; FUNDING; NOTE; ECONOMICS; ETHICS; FINANCIAL MANAGEMENT; HUMAN; INTERPERSONAL COMMUNICATION;

CLINICAL TRIALS AS TOPIC; CONFLICT OF INTEREST; DISCLOSURE; HUMANS; RESEARCH SUPPORT AS TOPIC;

EID: 85068785324     PISSN: 2515446X     EISSN: 25154478     Source Type: Journal    
DOI: 10.1136/bmjebm-2019-111230     Document Type: Note

References (17)

1. IOM (Institute of Medicine). Conflict of interest in medical research, education, and practice. Washington, DC: The National Academies Press, 2009.
2. Heneghan C, Godlee F. Surgical mesh and patient safety. BMJ 2018;363:k4231.
3. Shuchman M. Stopping the slide to research fraud. CMAJ 2017;189:E256-7.
4. Kupferschmidt K. Researcher at the center of an epic fraud remains an enigma to those who exposed him. Science 2018:1-45.
5. Boutron I, Dutton S, Ravaud P, et al. Reporting and interpretation of randomized controlled trials with statistically nonsignificant results for primary outcomes. JAMA 2010;303:2058-64.
6. Wang AT, McCoy CP, Murad MH, et al. Association between industry affiliation and position on cardiovascular risk with rosiglitazone: cross sectional systematic review. BMJ 2010;340:c1344.
7. Hakoum MB, Jouni N, Abou-Jaoude EA, et al. Characteristics of funding of clinical trials: cross-sectional survey and proposed guidance. BMJ Open 2017;7:1-10.
8. Ahn R, Woodbridge A, Abraham A, et al. Financial ties of principal investigators and randomized controlled trial outcomes: cross sectional study. BMJ 2017;356:i6770.
9. Lundh A, Lexchin J, Mintzes B, et al. Industry sponsorship and research outcome. Cochrane Database Syst Rev 2017;2:MR000033.
10. McGauran N, Wieseler B, Kreis J, et al. Reporting bias in medical research-A narrative review. Trials 2010;11:37.
11. Page MJ, Boutron I, Hansen C, et al. Assessing risk of bias in studies that evaluate health care interventions: recommendations in the misinformation age. J Clin Epidemiol 2018;97:133-6.
12. Wiersma M, Kerridge I, Lipworth W. Dangers of neglecting non-financial conflicts of interest in health and medicine. J Med Ethics 2017:1-4.
13. International Committee of Medical Journal Editors. Recommendations for the conduct, reporting, editing and publication of scholarly work in medical journals. 2018. http://www. icmje. org/recommendations (Accessed 27 May 2019).
14. Licurse A, Barber E, Joffe S, et al. The impact of disclosing financial ties in research and clinical care: A systematic review. Arch Intern Med 2010;170:675-82.
15. Roseman M, Milette K, Bero LA, et al. Reporting of conflicts of interest in meta-Analyses of trials of pharmacological treatments. JAMA 2011;305:1008-17.
16. Jørgensen L, Paludan-Möller AS, Laursen DR, et al. Evaluation of the Cochrane tool for assessing risk of bias in randomized clinical trials: overview of published comments and analysis of user practice in Cochrane and non-Cochrane reviews. Syst Rev 2016;5:80.
17. Boutron I, Page MJ, Higgins JPT, et al. Chapter 7: Considering bias and conflicts of interest among the included studies. Draft version (15 September 2018) for inclusion. In: Higgins JPT, Thomas J, Chandler J, eds. Cochrane Handbook for Systematic Reviews of Interventions. London: Cochrane.